Challenges & prospects in Nephrology

Sunday, December 7

K.1. Quality of Care and patient safety in HD Units

1. WHO Quality of Care & patient safety policy

2. Greek national policy

3. The NHS paradigm

4. The role of the Renal registries

5. Patient reported experience and outcome measures

6. Empowering patients to get their voice heard

K.2. Cardiovascular morbidity in CKD

1. Treatment of hyperlipidemia: what's new?

2. Challenges in the treatment of heart failure

3. Resistant and secondary hypertension

D.4. Hypertension guidelines in patients with CKD

K.3. Cardio-renal-metabolic syndrome

1. Guidelines: how to apply them in clinical practice?

2. The place of GLP-1 agonists in clinical practice

3. Application of the guidelines to patients with end-stage CKD

D.5. SGLT2 inhibitors: are they all the same?

K.4. Systemic diseases

1. KDIGO guidelines for polycystic kidney disease

2. Fabry disease: what's new?

D.6. Treatment options for lupus nephritis

General meeting - elections for the appointment of a new Board of Directors.

K.5. Latest news on IgA nephropathy

1. Topical release budesonide or sparsentan

2. What comes with IgA nephropathy?

D.7. How do I treat the patient with IgA nephropathy?

K.6. Latest in hemodialysis

1. HIF inhibitors: their place in clinical practice

2. What's new in the treatment of hyperphosphatemia?

3. What's new in uremic pruritus?

4. How do I treat the patient with hyperparathyroidism?

D.8. Vadadoustat: INNO 2 VATE trials and clinical use

P.1. Poster session

P.2. Practical exercise: Fistula puncture with ultrasound guidance